Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.28Akums Drugs & Pharmaceuticals Ltd showcases a dual financial profile. On one hand, the company demonstrates exceptional financial stability, characterized by extremely low debt levels and a balance sheet heavily funded by equity. This minimizes financial risk. Profitability is another key strength, with strong margins and high returns on both equity and capital employed. However, this is contrasted by significant operational weaknesses. The company is inefficient in using its assets and capital to generate sales, and it takes a considerable time to sell inventory and collect payments from customers. Growth has been volatile, with strong revenue and asset expansion but accompanied by severely negative earnings per share growth historically. Projections point towards a significant improvement in liquidity and income, but this hinges on turning its large asset base into efficient and stable profits.
Health Score : 7.28Akums Drugs & Pharmaceuticals Ltd showcases a dual financial profile. On one hand, the company demonstrates exceptional financial stability, characterized by extremely low debt levels and a balance sheet heavily funded by equity. This minimizes financial risk. Profitability is another key strength, with strong margins and high returns on both equity and capital employed. However, this is contrasted by significant operational weaknesses. The company is inefficient in using its assets and capital to generate sales, and it takes a considerable time to sell inventory and collect payments from customers. Growth has been volatile, with strong revenue and asset expansion but accompanied by severely negative earnings per share growth historically. Projections point towards a significant improvement in liquidity and income, but this hinges on turning its large asset base into efficient and stable profits.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
109.88
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
48.06
P/B RATIO
3.69
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
2.81
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
3.06
EV/EBITDA RATIO
16.85
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹779.05 as on Sep 1, 2026.
Growth Score : 8.00The company's growth profile is marked by extreme volatility and contrasts. On the positive side, it is expanding its asset base aggressively and shows strong revenue growth potential, with projections indicating a powerful recovery in operating profit. However, this is severely undermined by a very poor and erratic performance in earnings per share (EPS). The negative EPS growth is a significant red flag for shareholder value creation. This disparity suggests that while the company is getting bigger, this expansion has not translated into stable, profitable growth for its owners.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 34.85 | -0.46 | 14.31 | -1.44 | 5.85 |
| Operating Profit Growth Rate | -137.39 | 430.34 | -58.16 | 278.05 | 12.26 |
| Earnings Per Share (EPS) Growth | -103.74 | 118.78 | -104.22 | 7775 | -24.57 |
| Asset Growth Rate | 41.73 | 6.26 | 8.11 | 16.87 | 33.02 |
| Net Income Growth Rate | -304.07 | 139.04 | -98.98 | 34300 | -25.58 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 21 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Akums Drugs & Pharmaceuticals Ltd is a leading Indian contract development and manufacturing organization (CDMO) and third-party manufacturer of pharmaceutical formulations. It specializes in a wide array of dosage forms and therapeutic categories for domestic and international markets, operating extensive state-of-the-art manufacturing facilities and catering to a diverse client base.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Akums Drugs & Pharmaceuticals Ltd's P/E ratio (TTM) is 109.88, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Akums Drugs & Pharmaceuticals Ltd's P/B ratio is 3.69, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Akums Drugs & Pharmaceuticals Ltd's P/S ratio is 2.81, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Akums Drugs & Pharmaceuticals Ltd's PEG ratio is 3.06.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Akums Drugs & Pharmaceuticals Ltd's EV/EBITDA ratio is 16.85.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Akums Drugs & Pharmaceuticals Ltd's ROE is 7.72%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Akums Drugs & Pharmaceuticals Ltd's ROA is 9.58%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Akums Drugs & Pharmaceuticals Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Akums Drugs & Pharmaceuticals Ltd's operating margin is 11.98%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Akums Drugs & Pharmaceuticals Ltd's net margin is 5.87%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Akums Drugs & Pharmaceuticals Ltd's current ratio is 1.86.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Akums Drugs & Pharmaceuticals Ltd's debt-to-equity ratio is 0.02.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Akums Drugs & Pharmaceuticals Ltd's interest coverage ratio is 5.06.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Akums Drugs & Pharmaceuticals Ltd's DPS is ₹2.92.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Akums Drugs & Pharmaceuticals Ltd's EPS is -24.57.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹779.05. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Haridwar, Uttarakhand
Core Offerings: Contract Manufacturing (CDMO), Formulation Development, Finished Dosage Forms (tablets, capsules, injectables), Nutraceuticals, Ayush Products
Stock Listing: NSE (AKUMS), BSE (544222)
Promoter: Sanjeev Jain and Sandeep Jain / Jain Family
Akums Drugs & Pharmaceuticals Ltd was founded in 1990 by brothers Sanjeev Jain and Sandeep Jain. Starting with a single manufacturing unit, the company has grown significantly over three decades, establishing itself as one of India's largest contract manufacturers. It expanded its capabilities and product portfolio, investing in multiple state-of-the-art facilities. In 2023, Akums filed its Draft Red Herring Prospectus (DRHP) for an Initial Public Offering (IPO) to fund further expansion and debt reduction, marking a key milestone in its journey.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Domestic CDMO Services | Approximately 75% (FY23) | Operating Profit |
| Export CDMO Services | Approximately 25% (FY23) | Operating Profit |
Domestic & Export CDMO Services: Akums is primarily engaged in providing comprehensive contract development and manufacturing services for a vast range of pharmaceutical formulations to Indian and global pharmaceutical companies.
Extensive Dosage Forms: Specializes in manufacturing various finished dosage forms including tablets, capsules, injectables (liquid, dry powder, lyophilized), softgels, liquid orals, ointments, creams, sachets, dry syrups, and specialized products like hormones and nutraceuticals.
Therapeutic Areas: Caters to diverse therapeutic segments such as cardiology, diabetology, central nervous system (CNS), anti-infectives, gastroenterology, pain management, anti-inflammatory, dermatology, oncology, and vitamins/minerals.
Integrated Facilities: Operates multiple state-of-the-art manufacturing facilities in Haridwar, Uttarakhand, equipped with advanced technologies and adhering to global regulatory standards (e.g., USFDA, MHRA, TGA, Health Canada, WHO GMP).
Sanjeev Jain - Whole-time Director & CEO: Co-founder of Akums, he has over three decades of experience in the pharmaceutical manufacturing industry and is instrumental in the company's strategic growth and operational excellence. Sandeep Jain - Whole-time Director: Co-founder, with extensive experience in the pharma sector, he plays a crucial role in overseeing the company's manufacturing and business development initiatives.
Akums Life Sciences Limited
Akums Pharmaceuticals Limited
Pure & Cure Healthcare Private Limited
No major recent corporate actions on record (company is pre-IPO).
The Akums Drugs & Pharmaceuticals Ltd share price today is ₹779.05 on NSE (AKUMS), as of 26 Sept 2026.
As of 25 Sept 2026, Akums Drugs & Pharmaceuticals Ltd share price is ₹779.05, with previous close ₹779.05. Today's range is ₹779.05 to ₹779.05. The 52-week range is ₹409.30 to ₹838.80.
As of today, Akums Drugs & Pharmaceuticals Ltd's market cap is ₹12,231.08 crore (Mid Cap).
Akums Drugs & Pharmaceuticals Ltd's current P/E ratio is 109.88, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.
Akums Drugs & Pharmaceuticals Ltd's current P/B ratio is 3.69.
Akums Drugs & Pharmaceuticals Ltd's current dividend yield is 0.37%. Last dividend of ₹0.00 (Pre-IPO company, no public dividend record) per share was declared on N/A (Pre-IPO company).
Akums Drugs & Pharmaceuticals Ltd's EPS (TTM) is ₹-24.57.
Akums Drugs & Pharmaceuticals Ltd is a leading Indian contract development and manufacturing organization (CDMO) and third-party manufacturer of pharmaceutical formulations. It specializes in a wide array of dosage forms and therapeutic categories for domestic and international markets, operating extensive state-of-the-art manufacturing facilities and catering to a diverse client base.
Akums Drugs & Pharmaceuticals Ltd is promoted by Sanjeev Jain and Sandeep Jain / Jain Family, holding 75.26% as of 25 Sept 2026.
Akums Drugs & Pharmaceuticals Ltd is listed on NSE (AKUMS) and BSE (544222). Its next quarterly results are expected on N/A (Pre-IPO company).
